Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress on HIV latency-reversing agents and its mechanism

( views:52, downloads:1 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 6

DOI:: 10.3760/cma.j.issn.1674-2397.2021.06.011

Key Word:: HIV;HIV潜伏库;激活及清除;HIV潜伏感染激活剂;功能性治愈;HIV;HIV latent reservoirs;Shock and kill;HIV latency-reversing agents;Functional cure

Abstract： Human immunodeficiency virus (HIV) infection causes severe systemic immune system damage and ultimately leads to patient death. Despite the success of anti-retroviral therapy (ART), which can effectively supress viral replication, there is currently no cure for HIV infection, which requires lifelong treatment. Due to the presence of HIV latent reservoir, the virus persists during antiretroviral treatment. "Shock and Kill" is currently one of the most recognized strategies for removing HIV latent reservoir. The solution is mainly to reactivate viral transcription by using latency-reversing agents (LRAs), which triggers cell lysis or immune-mediated clearance to kill the reactivated HIV infected cells and achieve functional cure. This article gives an overview of current research progress on HIV LRAs and their mechanism of action.

Reference

[1]梁雪.黄芫花中HIV潜伏激活剂的发现及作用机制研究[D].2020.
[2]Guochun, Jiang,Satya, Dandekar.Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency.[J].2015,31.
[3].Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study[J].2015,2(12).
[4]Mbonye, Uri,Karn, Jonathan.The Molecular Basis for Human Immunodeficiency Virus Latency[J].2017,4.
[5]Clementine,Wallet,Marco,De Rovere,Jeanne,Van Assche,etc.Microglial Cells: The Main HIV-1 Reservoir in the Brain.[J].2019,9.
[6].Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?[J].2017,24.
[7].Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy[J].2017,91(8).
[8]Datta, Prasun K.,Kaminski, Rafal,Hu, Wenhui,etc.HIV-1 Latency and Eradication: Past, Present and Future[J].2016,14(5).
[9]R Brad, Jones,Stefanie, Mueller,Rachel, O'Connor,etc.A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.[J].2016.
[10]Novis Camille L,Archin Nancie M,Buzon Maria J,etc.Reactivation of latent HIV-1 in central memory CD4+T cells through TLR-1/2 stimulation[J].2013,10(1).
[11]T W, Chun,D, Engel,S B, Mizell,etc.Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.[J].1998,188(1).
[12].TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.[J].2018,10(439).
[13]Guochun,Jiang,Emanual,Maverakis,Michelle Y,Cheng,etc.Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.[J].2019,4(7).
[14]Gabriela M,Webb,Jhomary,Molden,Kathleen,Busman-Sahay,etc.The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.[J].2020,16(3).
[15]Zhu,H.,Qu,X.,Li,L.,etc.Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation[J].2013,440(2).
[16]Archin, Nancie M.,Kirchherr, Jennifer L.,Sung, Julia A. M.,etc.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency[J].2017,127(8).
[17]Bosque, Alberto,Famiglietti, Marylinda,Weyrich, Andrew S.,etc.Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+ T Cells.[J].2011,7(10).
[18]Gama, Lucio,Abreu, Celina M.,Shirk, Erin N.,etc.Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques[J].2017,31(1).
[19]Pache, Lars,Dutra, Miriam S.,Spivak, Adam M.,etc.BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency[J].2015,18(3).
[20]Campbell, Grant R.,Spector, Stephen A..DIABLO/SMAC mimetics selectively kill HIV-1-infected resting memory CD4(+) T cells: a potential role in a cure strategy for HIV-1 infection[J].2019,15(4).
[21]Carolina, Gutiérrez,Sergio, Serrano-Villar,Nadia, Madrid-Elena,etc.Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.[J].2016.
[22]Lisa N. McKernan,David Momjian,Joseph Kulkosky.Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs[J].2012,2012.
[23]Jiang,G.,Mendes,E.A.,Kaiser,P.,etc.Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling[J].2014,28(11).
[24]Wu, Yuntao,Li, Zichong,Guo, Jia,etc.The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation[J].2013,41(1).
[25]张志强,李石飞,张立伟,等.黄芫花化学成分及其抗乙肝病毒作用[J].2017,(7).
[26].Euphorbia Kansui Reactivates Latent HIV.[J].2016,(12).
[27]Panpan, Lu,Yinzhong, Shen,He, Yang,etc.BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.[J].2017,7(1).
[28]Chiara Acchioni,Anna Lisa Remoli,Giulia Marsili,etc.Alternate NF-\u03baB independent signaling re-activation of latent HIV-1 provirus[J].2019.
[29]Laird, Gregory M.,Bullen, C. Korin,Rosenbloom, Daniel I. S.,etc.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations[J].2015,125(5).
[30]Tania R C, Vergara,Sadia, Samer,Joanna R, Santos-Oliveira,etc.Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety.[J].2017,(Spec ).
[31]Emma,Morrish,Gabriela,Brumatti,John,Silke.Future Therapeutic Directions for Smac-Mimetics.[J].2020,9(2).
[32].HMBA Enhances Prostratin-Induced Activation of Latent HIV-1 via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-κB Signaling[J].2016.
[33]Jian Zhu,Gaurav D. Gaiha,Sinu P. John,etc.Reactivation of Latent HIV-1 by Inhibition of BRD4[J].2012,2(4).
[34]Thomas J. Nelson,Abhik Sen,Daniel L. Alkon,etc.Adduct formation in liquid chromatography-triple quadrupole mass spectrometric measurement of bryostatin 1[J].2014,944.
[35]Claire Vandergeeten,Rémi Fromentin,Sandrina Dafonseca,etc.Interleukin-7 promotes HIV persistence during antiretroviral therapy.[J].2013,121(21).
[36].The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.[J].2015,11(9).
[37]Wang FX,Xu Y,Sullivan J,etc.IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.[J].2005,115(1).
[38]Bradner,J.,Sebastiani,P.,Banerjee,C.,etc.BET bromodomain inhibition as a novel strategy for reactivation of HIV-1[J].2012,92(6).
[39]Gurinder Singh,Roopa S. Pai.Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS[J].2014,194.
[40]Kauder, Steven E.,Bosque, Alberto,Lindqvist, Annica,etc.Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation.[J].2009,5(6).
[41]Adam M Spivak,Adriana Andrade,Evelyn Eisele,etc.A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.[J].2014,58(6).
[42]Vibholm, Line K.,Konrad, Christina, V,Schleimann, Mariane H.,etc.Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+individuals[J].2019,33(8).
[43]Abner, Erik,Jordan, Albert.HIV "shock and kill" therapy: In need of revision[J].2019,166.
[44]Laura, Díaz,Marta, Martínez-Bonet,Javier, Sánchez,etc.Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-?B-dependent mechanism.[J].2015,5.
[45]Zerbato,J.,Sluis-Cremer,N.,Doyon,G.,etc.Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog[J].2013,27(2).
[46].H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4(+) T Cells[J].2015,89(16).
[47]Domcke Silvia,Bardet Anaïs Flore,Adrian Ginno Paul,etc.Competition between DNA methylation and transcription factors determines binding of NRF1[J].2015,528(7583).
[48]Panpan, Lu,Xiying, Qu,Yinzhong, Shen,etc.The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.[J].2016.
[49]Thomas A, Rasmussen,Martin, Tolstrup,Christel R, Brinkmann,etc.Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.[J].2014,1(1).
[50]Margolick, Joseph B.,Bullen, Cynthia K.,Yang, Hung-Chih,etc.Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4(+) T Cell Model without Inducing Global T Cell Activation[J].2011,85(12).
[51]Maria E, Riveiro,Lucile, Astorgues-Xerri,Ramiro, Vazquez,etc.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.[J].2016,(51).
[52]Campbell, Grant R.,Bruckman, Rachel S.,Chu, Yen-Lin,etc.SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+T Cells[J].2018,24(5).
[53]Offersen, Rasmus,Nissen, Sara Konstantin,Rasmussen, Thomas A.,etc.A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4(+) T Cells[J].2016,90(9).
[54]Castro-Gonzalez, Sergio,Colomer-Lluch, Marta,Serra-Moreno, Ruth.Barriers for HIV Cure: The Latent Reservoir[J].2018,34(9).
[55]Xiaoyun Zeng,Xiaoyan Pan.Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1[J].2017,65(22).
[56].Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.[J].2017,7(1).